IMVT Corporation

Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted therapies to enable normal lives for people with autoimmune diseases. The company is a trailblazer in anti‑FcRn technology and is advancing a pipeline of candidates through clinical trials across multiple therapeutic areas. Immunovant emphasizes patient and caregiver support while providing investor resources and corporate information. Headquartered in New York, it is publicly traded under the ticker IMVT.